



LindedIn Post

TheraPPI Bioscience Awarded the French Tech Emergence Grant

February 05, 2024 – Lyon, France

TheraPPI Bioscience SAS today announced that the company has been awarded the *French Tech Emergence* Grant by BPI France in the context of the “*Programme France 2030*”. This grant funding allows TheraPPI to pursue its R&D activities to offer treatments for drug-resistant cancers and non-curable rare diseases.

- ends -

Notes:

About TheraPPI Bioscience:

TheraPPI is preclinical-stage biotech company which develops protein interaction-modifying drugs to offer patients better treatments in oncology, rare diseases and inflammation. TheraPPI has been incubated within Pulsalys (French TTO of Lyon-St Etienne).

TheraPPI's two first programs target a novel MAPK protein interaction discovered by the founder team at the CRCL (University Claude Bernard Lyon 1, Inserm, Centre Léon Bérard and CNRS) in Lyon, France, in collaboration with the C3D technology platform of Lyon (Centre for Drug Discovery and Development) and with the support of Hospices Civils de Lyon..

The prognosis of patients with advanced cancers remains poor. The MAPK signaling is hyperactivated in over 40% of human cancers and MAPK-activating mutations cause rare diseases. The efficacy of current MAPK Inhibitors is undercut by cancer resistance and by their inability to cure these rare diseases.

TheraPPI's lead program in oncology revolutionizes RAS-MAPK targeting: the new mode of action leverages three mechanisms with direct killing cancer cells, no resistance induction and activation of an anti-tumoral immune response.

TheraPPI's lead program aims to obtain a high rate of clinical responses, to circumvent cancer resistance and to improve the response of immunotherapies and thus to offer a better prognosis to patients with advanced cancer.

Read more: <https://tppibio.com/>

Follow us on LinkedIn: <https://www.linkedin.com/therappi-bioscience/>

Forward Looking Statements:

This press release includes forward-looking statements and assumptions which reflect the management's current views of future events and operations. These forward-looking statements involve certain significant risks and uncertainties, and actual results may (negatively or positively) differ substantially from the forward-looking statements described explicitly or implicitly by TheraPPI.

Contacts:

TheraPPI Bioscience

Luc Otten

CEO and co-founder

info@tppibio.com